ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is OncoCyte Corp. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -33.98
2
The company has declared negative results for the last 3 consecutive quarters
- NET SALES(HY) At USD 0.27 MM has Grown at -89.8%
- OPERATING CASH FLOW(Y) Lowest at USD -26.95 MM
- RAW MATERIAL COST(Y) Grown by 411.33% (YoY)
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 29.90%, its profits have fallen by -28.8%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is OncoCyte Corp. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
OncoCyte Corp.
29.9%
0.44
102.22%
S&P 500
15.76%
1.20
13.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
34.18%
EBIT Growth (5y)
0.81%
EBIT to Interest (avg)
-33.98
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.90
Sales to Capital Employed (avg)
0.14
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
55.22%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-3.64
EV to EBIT
-3.40
EV to EBITDA
-3.66
EV to Capital Employed
-2.48
EV to Sales
25.65
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend2What is working for the Company
NET PROFIT(HY)
Higher at USD -19.15 MM
-23What is not working for the Company
NET SALES(HY)
At USD 0.27 MM has Grown at -89.8%
OPERATING CASH FLOW(Y)
Lowest at USD -26.95 MM
RAW MATERIAL COST(Y)
Grown by 411.33% (YoY
DEBT-EQUITY RATIO
(HY)
Highest at 74.46 %
PRE-TAX PROFIT(Q)
Fallen at -28.94%
NET PROFIT(Q)
Fallen at -28.94%
Here's what is not working for OncoCyte Corp.
Net Sales
At USD 0.27 MM has Grown at -89.8%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Operating Cash Flow
Lowest at USD -26.95 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Pre-Tax Profit
Fallen at -28.94%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Fallen at -28.94%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Debt-Equity Ratio
Highest at 74.46 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 411.33% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
